Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo Plus FLOT for Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 10, 2025 778 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Woman, 88, Had Been Waving from Her Window for Over a... May 13, 2019 Fourth Vaccine Dose Increases in Humoral Immunity Against Omicron Variants in... October 3, 2022 Reduction Not Only in Recurrences, but Also in Mortality, Observed for... December 20, 2022 Teacher Is Glad She Asked for More Testing After Mammogram Failed... October 28, 2020 Load more HOT NEWS Groundbreaking Physicist Uses Laser Technology To Kill Cancer Cells Without Any... EMA Recommends Extension of Therapeutic Indications for Cabozantinib and Nivolumab Loss of Y Chromosome in Men Makes Bladder Cancer More Aggressive The Most Successful Female Singer Of The 1970s Disappeared. Now She’s...
